01.31.11
Catalent Pharma Solutions has entered into an agreement with Nuron Biotech for the formulation and supply of NU100 (interferon beta-1b), a proprietary recombinant human interferon beta compound being developed for the treatment of multiple sclerosis (MS).
NU100 will be produced at Catalent’s facility in Brussels, Belgium, where this injectable product will be formulated, filled and packaged in a prefilled syringe. Nuron Biotech is currently planning to take NU100 into Phase III clinical trials in 2011.
“For decades, Catalent’s sterile technology business has a proven track record of partnering with innovators like Nuron Biotech to efficiently take products to market faster. We are excited to have the opportunity to apply our sterile delivery expertise to support Nuron through this complex and important stage of product development,” said Sheila Dell, Ph.D., vice president Business Development, Catalent. “In addition to preparing and supplying NU100 for Phase III trials, we are pleased to be able to support commercial manufacturing during the product’s first three years on the market.”
“Our senior managers have come to know and trust the Catalent team during previous business relationships, and we are pleased to re-establish this mutually beneficial partnership,” commented Nuron Biotech's chief executive officer and founder, Shankar Musunuri, Ph.D., MBA. “We have strong confidence in Catalent’s ability to support Nuron with NU100 and with other future scale-up and launch opportunities.”
NU100 will be produced at Catalent’s facility in Brussels, Belgium, where this injectable product will be formulated, filled and packaged in a prefilled syringe. Nuron Biotech is currently planning to take NU100 into Phase III clinical trials in 2011.
“For decades, Catalent’s sterile technology business has a proven track record of partnering with innovators like Nuron Biotech to efficiently take products to market faster. We are excited to have the opportunity to apply our sterile delivery expertise to support Nuron through this complex and important stage of product development,” said Sheila Dell, Ph.D., vice president Business Development, Catalent. “In addition to preparing and supplying NU100 for Phase III trials, we are pleased to be able to support commercial manufacturing during the product’s first three years on the market.”
“Our senior managers have come to know and trust the Catalent team during previous business relationships, and we are pleased to re-establish this mutually beneficial partnership,” commented Nuron Biotech's chief executive officer and founder, Shankar Musunuri, Ph.D., MBA. “We have strong confidence in Catalent’s ability to support Nuron with NU100 and with other future scale-up and launch opportunities.”